Revance Therapeutics, Inc.

NasdaqGM:RVNC Voorraadrapport

Marktkapitalisatie: US$547.2m

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Revance Therapeutics Beheer

Beheer criteriumcontroles 2/4

De CEO Revance Therapeutics' is Mark Foley, benoemd in Oct2019, heeft een ambtstermijn van 7.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 10.07M, bestaande uit 7.2% salaris en 92.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.06% van de aandelen van het bedrijf, ter waarde $ 5.74M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.3 jaar en 5.3 jaar.

Belangrijke informatie

Mark Foley

Algemeen directeur

US$10.1m

Totale compensatie

Percentage CEO-salaris7.2%
Dienstverband CEO5yrs
Eigendom CEO1.1%
Management gemiddelde ambtstermijn5.3yrs
Gemiddelde ambtstermijn bestuur5.3yrs

Recente managementupdates

Recent updates

Revance Therapeutics: Crown Merger Red Flags Makes For Problematic Call On Shares

Sep 26

Revance Therapeutics: Problems Mounting Amid Legal And Financial Woes

Jun 20

What Revance Therapeutics, Inc.'s (NASDAQ:RVNC) 30% Share Price Gain Is Not Telling You

Mar 04
What Revance Therapeutics, Inc.'s (NASDAQ:RVNC) 30% Share Price Gain Is Not Telling You

Revance: Stock Bouncing On Q4 Earnings, But Long-Term Challenges Remain

Feb 29

Revenues Not Telling The Story For Revance Therapeutics, Inc. (NASDAQ:RVNC) After Shares Rise 27%

Dec 28
Revenues Not Telling The Story For Revance Therapeutics, Inc. (NASDAQ:RVNC) After Shares Rise 27%

Analysts Are More Bearish On Revance Therapeutics, Inc. (NASDAQ:RVNC) Than They Used To Be

Nov 10
Analysts Are More Bearish On Revance Therapeutics, Inc. (NASDAQ:RVNC) Than They Used To Be

Here's Why Revance Therapeutics (NASDAQ:RVNC) Can Afford Some Debt

Aug 10
Here's Why Revance Therapeutics (NASDAQ:RVNC) Can Afford Some Debt

Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Earnings Haven't Escaped The Attention Of Investors

Jun 14
Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Earnings Haven't Escaped The Attention Of Investors

Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?

Apr 17
Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?

Revance Therapeutics (NASDAQ:RVNC) Is Making Moderate Use Of Debt

Jan 02
Revance Therapeutics (NASDAQ:RVNC) Is Making Moderate Use Of Debt

Revance Therapeutics submits sBLA for Daxxify for cervical dystonia

Oct 20

Revance climbs 14% as FDA approves facial injectable for frown lines

Sep 08

Revance Therapeutics: More Risk To Sept. 8 PDUFA Than It Seems

Aug 24

Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?

Aug 04
Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?

Analyse CEO-vergoeding

Hoe is Mark Foley's beloning veranderd ten opzichte van Revance Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$304m

Mar 31 2024n/an/a

-US$325m

Dec 31 2023US$10mUS$720k

-US$324m

Sep 30 2023n/an/a

-US$394m

Jun 30 2023n/an/a

-US$337m

Mar 31 2023n/an/a

-US$341m

Dec 31 2022US$7mUS$673k

-US$356m

Sep 30 2022n/an/a

-US$274m

Jun 30 2022n/an/a

-US$263m

Mar 31 2022n/an/a

-US$274m

Dec 31 2021US$7mUS$660k

-US$281m

Sep 30 2021n/an/a

-US$297m

Jun 30 2021n/an/a

-US$303m

Mar 31 2021n/an/a

-US$292m

Dec 31 2020US$9mUS$650k

-US$282m

Sep 30 2020n/an/a

-US$249m

Jun 30 2020n/an/a

-US$209m

Mar 31 2020n/an/a

-US$186m

Dec 31 2019US$18mUS$190k

-US$159m

Sep 30 2019n/an/a

-US$155m

Jun 30 2019n/an/a

-US$146m

Mar 31 2019n/an/a

-US$143m

Dec 31 2018US$243kn/a

-US$143m

Sep 30 2018n/an/a

-US$138m

Jun 30 2018n/an/a

-US$136m

Mar 31 2018n/an/a

-US$128m

Dec 31 2017US$338kn/a

-US$121m

Compensatie versus markt: De totale vergoeding ($USD 10.07M ) Mark } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.40M ).

Compensatie versus inkomsten: De vergoeding van Mark is gestegen terwijl het bedrijf verliesgevend is.

CEO

Mark Foley (59 yo)

5yrs

Tenure

US$10,068,915

Compensatie

Mr. Mark J. Foley serves as Chairman of uLab Systems, Inc. He has been Chief Executive Officer at Revance Therapeutics, Inc. since October 13, 2019 and served as its President since October 13, 2019 until...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Mark Foley
CEO & Director5yrsUS$10.07m1.06%
$ 5.8m
Tobin Schilke
CFO & Principal Accounting Officer5.9yrsUS$3.97m0.093%
$ 506.4k
Dwight Moxie
Chief Legal Officer & General Counsel4.7yrsUS$3.53m0.046%
$ 249.6k
Jessica Serra
Head of Investor Relations & ESGno datageen gegevensgeen gegevens
Jeanie Herbert
Senior Director of Investor Relations & Corporate Communications7.8yrsgeen gegevensgeen gegevens
Taryn Conway
Vice President of Marketing5.5yrsgeen gegevensgeen gegevens
Amie Krause
Chief People Officer1.6yrsgeen gegevensgeen gegevens
Conor Gallagher
Head of Medical Affairs & Aesthetics6.4yrsgeen gegevensgeen gegevens
David Hollander
Chief Medical Officer of Global Therapeutics Franchise Lead1.8yrsgeen gegevens0.0058%
$ 31.5k
Erica Jordan
Chief Commercial Officerno datageen gegevens0.11%
$ 599.6k

5.3yrs

Gemiddelde duur

49yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van RVNC is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.3 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Mark Foley
CEO & Director7.1yrsUS$10.07m1.06%
$ 5.8m
Angus Russell
Independent Chairman10.6yrsUS$346.03k0.049%
$ 268.9k
Jill Beraud
Independent Director5.3yrsUS$317.53k0.042%
$ 227.6k
Julian Gangolli
Independent Director8.3yrsUS$305.03k0.043%
$ 235.5k
Vladimir Coric
Independent Director1.6yrsUS$421.49k0.020%
$ 108.5k
Olivia Ware
Independent Director3.6yrsUS$295.03k0.030%
$ 165.4k
Carey Kolaja
Independent Director3.6yrsUS$304.18k0.030%
$ 164.8k
Christian Nolet
Independent Director5.3yrsUS$315.03k0.042%
$ 227.6k

5.3yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van RVNC wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.3 jaar).